Literature DB >> 24329187

Effect of CYP2D6 on risperidone pharmacokinetics and extrapyramidal symptoms in healthy volunteers: results from a pharmacogenetic clinical trial.

Patricia Gassó1, Sergi Mas, Katerina Papagianni, Eva Ferrando, Ramón Fernández de Bobadilla, Joan Albert Arnaiz, Miquel Bioque, Miquel Bernardo, Amalia Lafuente.   

Abstract

AIM: To elucidate the relationship between CYP2D6 genotype and risperidone pharmacokinetics and extrapyramidal symptoms we propose the APSEP pharmacogenetic clinical trial. MATERIALS &
METHODS: Twenty-five healthy subjects were included in this randomized, placebo-controlled, single dose (risperidone 2.5 mg) crossover and double-blind clinical trial. Subjects were selected according to their CYP2D6 genotype and classified as: poor metabolizers (n = 8), extensive metabolizers (n = 10) and ultrarapid metabolizers (n = 7). RESULTS &
CONCLUSION: Our study demonstrates that CYP2D6 predicted 65% of the risperidone metabolism variability. Moreover, its ability to predict actigraphy records is similar to the predictive power of pharmacokinetic parameters (24%). Our results also highlight the need for the development of pharmacogenetic predictors that take into account the complexity of pharmacokinetic and pharmacodynamic relationships.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24329187     DOI: 10.2217/pgs.13.204

Source DB:  PubMed          Journal:  Pharmacogenomics        ISSN: 1462-2416            Impact factor:   2.533


  2 in total

Review 1.  Genetics of Common Antipsychotic-Induced Adverse Effects.

Authors:  Raymond R MacNeil; Daniel J Müller
Journal:  Mol Neuropsychiatry       Date:  2016-05-20

2.  Sulforaphane from Broccoli Reduces Symptoms of Autism: A Follow-up Case Series from a Randomized Double-blind Study.

Authors:  Rhoda Lynch; Eileen L Diggins; Susan L Connors; Andrew W Zimmerman; Kanwaljit Singh; Hua Liu; Paul Talalay; Jed W Fahey
Journal:  Glob Adv Health Med       Date:  2017-10-26
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.